EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Polyfunctional CD 8 + CD 226 + RUNX 2 hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia

Maryam Rezaeifar, Shima Shahbaz, Anthea C Peters, Spencer B Gibson, Shokrollah Elahi iD

Molecular Oncology · 2025-05 · 19 (5) · 1347-1370

DOI: 10.1002/1878-0261.13793 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 07.01.2025. Verfasst von Maryam Rezaeifar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Foundational Sciences, Mike Petryk School of Dentistry, University of Alberta, Edmonton, Canada. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, CD8-Positive T-Lymphocytes, Antigens, Differentiation, T-Lymphocyte. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CD8 + T cells, a subset of T cells identified by the surface glycoprotein CD8, particularly those expressing the co‐stimulatory molecule CD226, play a crucial role in the immune response to malignancies. However, their role in chronic lymphocytic leukemia (CLL), an immunosuppressive disease, has not yet been explored. We studied 64 CLL patients and 25 age‐ and sex‐matched healthy controls (HCs). We analyzed the proportion of CD226‐expressing cells among different CD8 + T cell subsets (including naïve, central memory, effector memory, and effectors) in CLL patients, stratified by Rai stage and immunoglobulin heavy‐chain variable region gene (IgHV) mutation status. Additionally, we compared the effector functions of CD8 + CD226 + cells and their CD226 − counterparts. We also quantified cytokine and chemokine levels in the plasma of CLL and HCs. Furthermore, we reanalyzed the publicly available bulk RNA‐seq on CD226 + and CD226 − CD8 + T cells. Finally, we evaluated the impact of elevated cytokines/chemokines on CD226 expression. Our results showed that CD226 ‐expressing cells were significantly decreased within the effector memory and effector CD8 + T cell subsets in CLL patients with advanced Rai stages and unmutated IgHV, a marker of poor prognosis. These cells displayed robust effector functions, including cytokine production, cytolytic activity, degranulation, proliferation, and migration capacity. In contrast, CD8 + CD226 − T cells displayed an exhausted phenotype with reduced Runt‐related transcription factor 2 ( RUNX2 ) expression. Elevated levels of interleukin‐6 (IL‐6) and macrophage inflammatory protein‐1 beta (MIP‐1β) were inversely correlated with the frequency of CD8 + CD226 + T cells and may contribute to the downregulation of CD226, possibly leading to T cell dysfunction in CLL. Our findings highlight the critical role of CD8 + CD226 + RUNX2 hi T cells in CLL and suggest that their reduction is associated with disease progression and poor clinical outcomes. This study also underscores the potential of targeting IL‐6 and MIP‐1β to preserve polyfunctional CD8 + CD226 + T cells as a promising immunotherapy strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellCD8-Positive T-LymphocytesAntigens, Differentiation, T-LymphocyteHumansFemaleMaleMiddle AgedAgedCytokinesT Lineage-Specific Activation Antigen 1Neoplasm StagingCase-Control Studies

Stichwörter der Autor:innen

CD29+ T cellIL‐6 and MIP‐1βNK‐T cell‐likeco‐inhibitory receptors

Substanzen

Antigens, Differentiation, T-LymphocyteCytokinesT Lineage-Specific Activation Antigen 1

Autor:innen und Institutionen

  • Division of Foundational Sciences, Mike Petryk School of Dentistry, University of Alberta, Edmonton, Canada.
  • Division of Medical Oncology, Department of Oncology, University of Alberta, Edmonton, Canada.
  • Department of Biochemistry and Medical Genetics, University of Alberta, Edmonton, Canada.
  • Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada.
  • Women and Children Health Research Institute, University of Alberta, Edmonton, Canada.
  • Cancer Research Institute of Northern Alberta, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada.

ORCID-Profile: Shokrollah Elahi

Förderung

  • Cancer Research Society

Zitieren

APA

Rezaeifar, M., Shahbaz, S., Peters, A. C., Gibson, S. B., & Elahi, S. (2025). Polyfunctional CD 8 + CD 226 + RUNX 2 hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia. Molecular Oncology, 19(5), 1347-1370. https://doi.org/10.1002/1878-0261.13793

Vancouver

Rezaeifar M, Shahbaz S, Peters AC, Gibson SB, Elahi S. Polyfunctional CD 8 + CD 226 + RUNX 2 hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia. Molecular Oncology. 2025;19(5):1347-1370. doi:10.1002/1878-0261.13793

BibTeX
@article{Rezaeifar2025,
  author = {Rezaeifar, Maryam and Shahbaz, Shima and Peters, Anthea C and Gibson, Spencer B and Elahi, Shokrollah},
  title = {Polyfunctional CD 8 + CD 226 + RUNX 2 hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia},
  journal = {Molecular Oncology},
  year = {2025},
  volume = {19},
  number = {5},
  pages = {1347--1370},
  doi = {10.1002/1878-0261.13793}
}
Kostenlos starten →